When she started college, Anne Carpenter, Ph.D., never guessed she’d one day create software for analyzing images of cells that would help identify potential medicines and that thousands of researchers would use. She wasn’t planning to become a computational biologist, or even to focus on science at all, but she’s now an institute scientist and the senior director of the Imaging Platform at the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard in Cambridge.

Starting Out in Science

Before beginning her undergraduate studies at Purdue University in West Lafayette, Indiana, Dr. Carpenter’s strongest interests were reading and writing. Then, her subjects expanded. “In college, I liked science as much as anything else, and I realized that was unusual, as a lot of other people really struggled with it. I decided to pursue science because I enjoyed it and the field had good job prospects,” she says. Dr. Carpenter majored in biology because she felt it had the “juiciest questions” as well as a direct impact on human health.

The year 2022 marked 50 years since the creation of the NIGMS Human Genetic Cell Repository (HGCR) at the Coriell Institute for Medical Research in Camden, New Jersey. The NIGMS HGCR consists of cell lines and DNA samples with a focus on those from people with rare, heritable diseases. “Many rare diseases now have treatments because of the samples in the NIGMS HGCR,” says Nahid Turan, Ph.D., Coriell’s chief biobanking officer and co-principal investigator of the NIGMS HGCR. She gives the example of a rare disease advocacy group who worked with the NIGMS HGCR to establish a cell line several decades ago. It was used to identify a gene associated with the disease, which aided in the development of five treatments that have received approval from the Food and Drug Administration.

Researchers have also studied NIGMS HGCR’s samples to help advance knowledge of basic biology and genetics, and even to support the development of a vaccine for a deadly virus.

Students with blindness and low vision are often excluded from chemistry labs and offered few accessible representations of the subject’s imagery, which can significantly hinder their ability to learn about and participate in chemistry. Bryan Shaw, Ph.D., a professor of chemistry and biochemistry at Baylor University in Waco, Texas, hopes to change that through a program funded by an NIGMS Science Education Partnership Award (SEPA). His inspiration to start the program came from his son, who is visually impaired due to childhood eye cancer, and his son’s friends who have also experienced partial or complete vision loss.

“I have a hard time envisioning a career more exciting than science. It’s really magical to see an experimental result and, for a moment, be the only person in the universe to know something about the world,” says Markita Landry, Ph.D., an associate professor of chemical and biomolecular engineering at the University of California, Berkeley. In an interview, Dr. Landry shares with us her scientific journey, research with nanoparticles, and interests outside of the lab.

Q: What sparked your interest in science?

A: I was indirectly exposed to science growing up because my mom was in computer science, but I think moving to the United States is what made me very interested in it. My mother is Bolivian; my father is French-Canadian; and I grew up mostly in Quebec, Canada. When I was halfway through high school, we moved to the United States, and, for the first time, my classes were taught in English. I really gravitated to math and science because they made sense regardless of the language they were taught in.

Since its creation in 1962, NIGMS has supported the work of the recipients of 94 Nobel Prizes—44 in physiology or medicine and 50 in chemistry. NIGMS-funded investigators perform cutting-edge basic research that is foundational to understanding normal life processes and disease. Such important breakthroughs in chemistry and biology often fuel more focused research that, years later, leads to important medical advances or products such as medicines or biotechnology tools.

The most recent NIGMS-supported Nobel laureates are Carolyn R. Bertozzi, Ph.D., the Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences at Stanford University in Stanford, California, and K. Barry Sharpless, Ph.D., the W.M. Keck Professor of Chemistry at the Scripps Research Institute in La Jolla, California. They, along with Morten Meldal, Ph.D., a professor of chemistry at the University of Copenhagen in Denmark, are being recognized with the 2022 Nobel Prize in chemistry for their work on a transformative scientific approach known as “click chemistry.” The three scientists will receive their awards during a ceremony in Stockholm, Sweden, on December 10, 2022.

“Being able to ground your research in questions coming directly from your patients and their families is so meaningful and a huge part of why I’m interested in becoming a clinician-scientist,” says Amelia Wilhelm, an M.D.-Ph.D. student in the NIGMS-supported Medical Scientist Training Program (MSTP) at the University of Washington in Seattle. MSTPs prepare students to combine clinical practice and rigorous scientific research in their future careers.

Continuing the Family Tradition in Science

As a child of two scientists, Amelia was exposed to research and medical careers from an early age. She earned a bachelor’s degree in chemistry at Bates College in Lewiston, Maine, and then began working as a lab technician at the Children’s Hospital of Philadelphia in Pennsylvania. Watching the principal investigator of her lab, clinician-scientist Lindsey A. George, M.D., interact with patients inspired Amelia to pursue a similar career.

Public health crises often disproportionately impact rural America. Sally L. Hodder, M.D., works to alleviate these disparities, especially regarding the opioid crisis and the COVID-19 pandemic. She’s the director of the West Virginia Clinical and Translational Science Institute (WVCTSI), the associate vice president of clinical and translational research, and a professor of medicine at West Virginia University.

Dr. Hodder’s work is focused in West Virginia, but her results are valuable assets to researchers across the country. Not only does treating chronic diseases in rural populations contribute to the overall understanding of those diseases, but engaging with and involving people in those communities in research makes science more accessible to them. Dr. Hodder says, “When folks participate in the science, when there is good community discussion about the trial designs and the results, then I think those populations may be more trusting of the results."

Just as electricity powers almost every modern gadget, the tiny molecule adenosine triphosphate (ATP) is the major source of energy for organisms’ biochemical reactions. ATP stores energy in the chemical bonds that hold its three phosphate groups together—the triphosphate part of its name. In the human body, ATP powers processes such as cell signaling, muscle contraction, nerve firing, and DNA and RNA synthesis. Because our cells are constantly using and producing ATP, each of us turns over roughly our body weight in the molecule every day!

Our bodies can produce ATP in several ways, but the most common is cellular respiration—a multistep process in which glucose molecules from our diet and oxygen react to form water and carbon dioxide. The breakdown of a single molecule of glucose in this way releases energy, which the body captures and stores in around 32 ATP molecules. Along with oxygen, mitochondria are crucial for producing ATP through cellular respiration, which is why they’re sometimes called the powerhouses of cells.